JULIAN LAGOY: Open Payments
NPI 1053706861 · SAN JOSE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,116 in 93 payments from 13 companies in 2025. Trend: 2023 $1,298 · 2024 $1,410 · 2025 $2,116
Food & beverage: $2,116
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $505 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $360 |
| Otsuka America Pharmaceutical, Inc. | 11 | $252 |
| Axsome Therapeutics, Inc. | 8 | $251 |
| Alkermes, Inc. | 9 | $207 |
| Janssen Pharmaceuticals, Inc | 5 | $156 |
| Lundbeck LLC | 5 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| E.R. Squibb & Sons, L.L.C. | 2 | $63 |
| Tris Pharma Inc | 2 | $49 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Auvelity, LYBALVI, ARISTADA, SPRAVATO, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
